BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, Esteva FJ, Buzdar AU, Chen H, Eksambi S, Hortobagyi GN, Baselga J, Gonzalez-Angulo AM. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 2009;15:7381-8. [PMID: 19920100 DOI: 10.1158/1078-0432.CCR-09-1735] [Cited by in Crossref: 190] [Cited by in F6Publishing: 99] [Article Influence: 14.6] [Reference Citation Analysis]
Number Citing Articles
1 Garousi J, Xu T, Liu Y, Vorontsova O, Hober S, Orlova A, Tolmachev V, Gräslund T, Vorobyeva A. Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart. Pharmaceutics 2022;14:1612. [DOI: 10.3390/pharmaceutics14081612] [Reference Citation Analysis]
2 Barakat A, Abu-serie MM, Ali M, Al-majid AM, Ashraf S, Zia K, Ul-haq Z, Al-dhfyan A, Abdel-aziz HA, El-faham A, Domingo LR. Synthesis, In Vitro and in Cell Study of a New Spirooxindoles-Based N -Alkylated Maleimides Targeting HER2/3 Signaling Pathway. Polycyclic Aromatic Compounds. [DOI: 10.1080/10406638.2022.2101486] [Reference Citation Analysis]
3 Loria R, Vici P, Di Lisa FS, Soddu S, Maugeri-saccà M, Bon G. Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue. Front Oncol 2022;12:877380. [DOI: 10.3389/fonc.2022.877380] [Reference Citation Analysis]
4 Yu J, Li NL. Loss of human epidermal receptor-2 in human epidermal receptor-2+ breast cancer after neoadjuvant treatment: A case report. World J Clin Cases 2022; 10(17): 5923-5928 [DOI: 10.12998/wjcc.v10.i17.5923] [Reference Citation Analysis]
5 Miglietta F, Griguolo G, Bottosso M, Giarratano T, Lo Mele M, Fassan M, Cacciatore M, Genovesi E, De Bartolo D, Vernaci G, Amato O, Porra F, Conte P, Guarneri V, Dieci MV. HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment. NPJ Breast Cancer 2022;8:66. [PMID: 35595761 DOI: 10.1038/s41523-022-00434-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Stucci LS, Pisino M, D’addario C, Grassi T, Toss A. Management of HER2-Positive Early Breast Cancer in Italy: A Maze Presenting Opportunities and Challenges. Front Oncol 2022;12:871160. [DOI: 10.3389/fonc.2022.871160] [Reference Citation Analysis]
7 O'Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, Leon-Ferre R, Hurvitz SA, Kalinsky K, Bardia A, Henry S, Mayer I, Zhu Y, Phan S, Cortés J. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Res Treat 2022. [PMID: 35545724 DOI: 10.1007/s10549-022-06602-7] [Reference Citation Analysis]
8 Chakravarty D, Johnson A, Sklar J, Lindeman NI, Moore K, Ganesan S, Lovly CM, Perlmutter J, Gray SW, Hwang J, Lieu C, André F, Azad N, Borad M, Tafe L, Messersmith H, Robson M, Meric-Bernstam F. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol 2022;40:1231-58. [PMID: 35175857 DOI: 10.1200/JCO.21.02767] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Wynn CS, Tang SC. Anti-HER2 therapy in metastatic breast cancer: many choices and future directions. Cancer Metastasis Rev 2022. [PMID: 35142964 DOI: 10.1007/s10555-022-10021-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Chen Y, Liu X, Yu K, Sun X, Xu S, Qiu P, Lv Z, Zhang X, Guo A, Xu Y. Impact of hormone receptor, HER2, and Ki-67 status conversions on survival after neoadjuvant chemotherapy in breast cancer patients: a retrospective study. Ann Transl Med 2022;10:93. [PMID: 35282081 DOI: 10.21037/atm-21-6924] [Reference Citation Analysis]
11 Tan ZC, Orcutt-Jahns BT, Meyer AS. A quantitative view of strategies to engineer cell-selective ligand binding. Integr Biol (Camb) 2021:zyab019. [PMID: 34931243 DOI: 10.1093/intbio/zyab019] [Reference Citation Analysis]
12 Coiro S, Gasparini E, Falco G, Santandrea G, Foroni M, Besutti G, Iotti V, Di Cicilia R, Foroni M, Mele S, Ferrari G, Bisagni G, Ragazzi M. Biomarkers Changes after Neoadjuvant Chemotherapy in Breast Cancer: A Seven-Year Single Institution Experience. Diagnostics 2021;11:2249. [DOI: 10.3390/diagnostics11122249] [Reference Citation Analysis]
13 Allegretti M, Fabi A, Giordani E, Ercolani C, Romania P, Nisticò C, Gasparro S, Barberi V, Ciolina M, Pescarmona E, Giannarelli D, Ciliberto G, Cognetti F, Giacomini P. Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer. Mol Cancer 2021;20:151. [PMID: 34839818 DOI: 10.1186/s12943-021-01438-z] [Reference Citation Analysis]
14 Viale G, Fusco N. Pathology after neoadjuvant treatment - How to assess residual disease. Breast 2021:S0960-9776(21)00990-5. [PMID: 34810049 DOI: 10.1016/j.breast.2021.11.009] [Reference Citation Analysis]
15 Díaz-Gil L, Brasó-Maristany F, Locatelli C, Centa A, Győrffy B, Ocaña A, Prat A, Pandiella A. Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer. J Exp Clin Cancer Res 2021;40:313. [PMID: 34620206 DOI: 10.1186/s13046-021-02098-z] [Reference Citation Analysis]
16 Lu Y, Tong Y, Chen X, Shen K. Association of Biomarker Discrepancy and Treatment Decision, Disease Outcome in Recurrent/Metastatic Breast Cancer Patients. Front Oncol 2021;11:638619. [PMID: 34277399 DOI: 10.3389/fonc.2021.638619] [Reference Citation Analysis]
17 Kast F, Schwill M, Stüber JC, Pfundstein S, Nagy-Davidescu G, Rodríguez JMM, Seehusen F, Richter CP, Honegger A, Hartmann KP, Weber TG, Kroener F, Ernst P, Piehler J, Plückthun A. Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action. Nat Commun 2021;12:3790. [PMID: 34145240 DOI: 10.1038/s41467-021-23948-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Kennedy JJ, Whiteaker JR, Kennedy LC, Bosch DE, Lerch ML, Schoenherr RM, Zhao L, Lin C, Chowdhury S, Kilgore MR, Allison KH, Wang P, Hoofnagle AN, Baird GS, Paulovich AG. Quantification of Human Epidermal Growth Factor Receptor 2 by Immunopeptide Enrichment and Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded and Frozen Breast Cancer Tissues. Clin Chem 2021;67:1008-18. [PMID: 34136904 DOI: 10.1093/clinchem/hvab047] [Reference Citation Analysis]
19 Jeong YH, Hong SA, Ahn HS, Ahn SK, Kim MK. Clinicopathologic factors affecting discrepancies in HER2 overexpression between core needle biopsy and surgical biopsy in breast cancer patients according to neoadjuvant treatment or not. J Cancer 2021;12:4722-8. [PMID: 34149935 DOI: 10.7150/jca.59419] [Reference Citation Analysis]
20 Ruth JR, Pant DK, Pan TC, Seidel HE, Baksh SC, Keister BA, Singh R, Sterner CJ, Bakewell SJ, Moody SE, Belka GK, Chodosh LA. Cellular dormancy in minimal residual disease following targeted therapy. Breast Cancer Res 2021;23:63. [PMID: 34088357 DOI: 10.1186/s13058-021-01416-9] [Reference Citation Analysis]
21 Gameiro A, Nascimento C, Correia J, Ferreira F. HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models. Cancers (Basel) 2021;13:2007. [PMID: 33919468 DOI: 10.3390/cancers13092007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
22 Mohan SC, Walcott-Sapp S, Lee MK, Srour MK, Kim S, Amersi FF, Giuliano AE, Chung AP. Alterations in Breast Cancer Biomarkers Following Neoadjuvant Therapy. Ann Surg Oncol 2021. [PMID: 33748896 DOI: 10.1245/s10434-021-09814-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Xu L, Liu Y, Fan Z, Jiang Z, Liu Y, Ling R, Zhang J, Yu Z, Jin F, Wang C, Cui S, Wang S, Mao D, Han B, Wang T, Zhang G, Wang T, Guo B, Yu L, Xu Y, Fu F, Liu Z, Wang S, Luo K, Xiang Q, Zhang Z, Liu Q, Zhou B, Liu Z, Ma C, Tong W, Mao J, Duan X, Cui Y. Assessment of CPS + EG, Neo-Bioscore and Modified Neo-Bioscore in Breast Cancer Patients Treated With Preoperative Systemic Therapy: A Multicenter Cohort Study. Front Oncol 2021;11:606477. [PMID: 33796452 DOI: 10.3389/fonc.2021.606477] [Reference Citation Analysis]
24 Yuan JQ, Ding NH, Xiao Z. The Hippo Transducer YAP/TAZ as a Biomarker of Therapeutic Response and Prognosis in Trastuzumab-Based Neoadjuvant Therapy Treated HER2-Positive Breast Cancer Patients. Front Pharmacol 2020;11:537265. [PMID: 32973536 DOI: 10.3389/fphar.2020.537265] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Zhang Y. The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance. Pharmacol Ther 2021;218:107677. [PMID: 32898548 DOI: 10.1016/j.pharmthera.2020.107677] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Jhaveri KL, Wang XV, Makker V, Luoh SW, Mitchell EP, Zwiebel JA, Sharon E, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann Oncol 2019;30:1821-30. [PMID: 31504139 DOI: 10.1093/annonc/mdz291] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 15.0] [Reference Citation Analysis]
27 Betts A, Clark T, Jasper P, Tolsma J, van der Graaf PH, Graziani EI, Rosfjord E, Sung M, Ma D, Barletta F. Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1. J Pharmacokinet Pharmacodyn 2020;47:513-26. [PMID: 32710210 DOI: 10.1007/s10928-020-09702-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
28 Chica-Parrado MR, Godoy-Ortiz A, Jiménez B, Ribelles N, Barragan I, Alba E. Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors. Cancers (Basel) 2020;12:E2012. [PMID: 32708049 DOI: 10.3390/cancers12082012] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Gogia A, Deo SVS, Sharma D, Phulia RK, Thulkar S, Malik PS, Mathur S. Discordance in Biomarker Expression in Breast Cancer After Metastasis: Single Center Experience in India. J Glob Oncol 2019;5:1-8. [PMID: 30951390 DOI: 10.1200/JGO.18.00184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Tintelnot J, Goekkurt E, Binder M, Thuss-Patience P, Lorenzen S, Knorrenschild JR, Kretzschmar A, Ettrich T, Lindig U, Jacobasch L, Pink D, Al-Batran SE, Hinke A, Hegewisch-Becker S, Nilsson S, Bokemeyer C, Stein A. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217). BMC Cancer 2020;20:503. [PMID: 32487035 DOI: 10.1186/s12885-020-06958-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
31 Zhang H, Moisini I, Ajabnoor RM, Turner BM, Hicks DG. Applying the New Guidelines of HER2 Testing in Breast Cancer. Curr Oncol Rep 2020;22:51. [PMID: 32346807 DOI: 10.1007/s11912-020-0901-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
32 Lu H, Yin J. Texture Analysis of Breast DCE-MRI Based on Intratumoral Subregions for Predicting HER2 2+ Status. Front Oncol 2020;10:543. [PMID: 32373531 DOI: 10.3389/fonc.2020.00543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Gris-Oliver A, Palafox M, Monserrat L, Brasó-Maristany F, Òdena A, Sánchez-Guixé M, Ibrahim YH, Villacampa G, Grueso J, Parés M, Guzmán M, Rodríguez O, Bruna A, Hirst CS, Barnicle A, de Bruin EC, Reddy A, Schiavon G, Arribas J, Mills GB, Caldas C, Dienstmann R, Prat A, Nuciforo P, Razavi P, Scaltriti M, Turner NC, Saura C, Davies BR, Oliveira M, Serra V. Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. Clin Cancer Res 2020;26:3720-31. [PMID: 32220884 DOI: 10.1158/1078-0432.CCR-19-3324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
34 Nadal-Serrano M, Morancho B, Escrivá-de-Romaní S, Morales CB, Luque A, Escorihuela M, Espinosa Bravo M, Peg V, Dijcks FA, Dokter WHA, Cortés J, Saura C, Arribas J. The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1. Cancers (Basel) 2020;12:E670. [PMID: 32183023 DOI: 10.3390/cancers12030670] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
35 Nagata H, Tsujimoto H, Yaguchi Y, Kouzu K, Itazaki Y, Ishibashi Y, Tsuchiya S, Sugihara T, Ito N, Harada M, Nomura S, Utsumi Y, Shimazaki H, Kishi Y, Ueno H. Mixed adenoneuroendocrine carcinoma with loss of HER2 positivity after trastuzumab-based chemotherapy for HER2-positive gastric cancer: a case report. Surg Case Rep 2020;6:5. [PMID: 31916037 DOI: 10.1186/s40792-020-0774-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Hunter FW, Barker HR, Lipert B, Rothé F, Gebhart G, Piccart-Gebhart MJ, Sotiriou C, Jamieson SMF. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. Br J Cancer 2020;122:603-12. [PMID: 31839676 DOI: 10.1038/s41416-019-0635-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
37 Li X, Wang M, Wang M, Yu X, Guo J, Sun T, Yao L, Zhang Q, Xu Y. Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy. J Breast Cancer 2019;22:497-521. [PMID: 31897326 DOI: 10.4048/jbc.2019.22.e49] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
38 Dumbrava EEI, Balaji K, Raghav K, Hess K, Javle M, Blum-Murphy M, Ajani J, Kopetz S, Broaddus R, Routbort M, Demirhan M, Zheng X, Pant S, Tsimberidou AM, Subbiah V, Hong DS, Rodon J, Shaw KM, Piha-Paul SA, Meric-Bernstam F. Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precis Oncol 2019;3:PO. [PMID: 32923865 DOI: 10.1200/PO.18.00345] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
39 Abraham J, Montero AJ, Jankowitz RC, Salkeni MA, Beumer JH, Kiesel BF, Piette F, Adamson LM, Nagy RJ, Lanman RB, Sperinde J, Huang W, Allegra CJ, Srinivasan A, Wang Y, Pogue-Geile KL, Lucas PC, Jacobs SA. Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10. J Clin Oncol 2019;37:2601-9. [PMID: 31442103 DOI: 10.1200/JCO.19.00858] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
40 Zoeller JJ, Vagodny A, Taneja K, Tan BY, O'Brien N, Slamon DJ, Sampath D, Leverson JD, Bronson RT, Dillon DA, Brugge JS. Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo. Mol Cancer Ther 2019;18:1115-26. [PMID: 30962322 DOI: 10.1158/1535-7163.MCT-18-0743] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
41 Ecker BL, Lee JY, Sterner CJ, Solomon AC, Pant DK, Shen F, Peraza J, Vaught L, Mahendra S, Belka GK, Pan TC, Schmitz KH, Chodosh LA. Impact of obesity on breast cancer recurrence and minimal residual disease. Breast Cancer Res 2019;21:41. [PMID: 30867005 DOI: 10.1186/s13058-018-1087-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
42 Shu S, Iimori M, Nakanishi R, Jogo T, Saeki H, Oki E, Maehara Y. Changes in HER2 Expression and Amplification Status Following Preoperative Chemotherapy for Gastric Cancer. In Vivo 2018;32:1491-8. [PMID: 30348707 DOI: 10.21873/invivo.11405] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
43 Robertson S, Rönnlund C, de Boniface J, Hartman J. Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant. Breast Cancer Res Treat 2019;174:795-805. [PMID: 30659433 DOI: 10.1007/s10549-018-05119-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
44 Peng JH, Zhang X, Song JL, Ran L, Luo R, Li HY, Wang YH. Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma. Medicine (Baltimore) 2019;98:e13554. [PMID: 30633152 DOI: 10.1097/MD.0000000000013554] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
45 Tanaka S, Luk S, Kiyokawa J, Onozato ML, Iafrate AJ, Shah K, Martuza RL, Rabkin SD, Batchelor TT, Cahill DP, Chi AS, Wakimoto H. Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy. Sci Rep 2019;9:139. [PMID: 30644426 DOI: 10.1038/s41598-018-37437-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
46 Yamaoka T, Kusumoto S, Ando K, Ohba M, Ohmori T. Receptor Tyrosine Kinase-Targeted Cancer Therapy. Int J Mol Sci 2018;19:E3491. [PMID: 30404198 DOI: 10.3390/ijms19113491] [Cited by in Crossref: 75] [Cited by in F6Publishing: 66] [Article Influence: 18.8] [Reference Citation Analysis]
47 Nami B, Maadi H, Wang Z. Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer. Cancers (Basel) 2018;10:E342. [PMID: 30241301 DOI: 10.3390/cancers10100342] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 9.8] [Reference Citation Analysis]
48 Xu L, Zhang Z, Liu Q, Zhou B, Liu Y, Xiang Q, Zhu S, Duan X, Cui Y. Validation of CPS+EG, Neo-Bioscore, and modified Neo-Bioscore staging systems after preoperative systemic therapy of breast cancer: Protocol of a retrospective multicenter cohort study in China. Thorac Cancer 2018;9:1565-72. [PMID: 30296013 DOI: 10.1111/1759-7714.12852] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
49 Bensch F, Brouwers AH, Lub-de Hooge MN, de Jong JR, van der Vegt B, Sleijfer S, de Vries EGE, Schröder CP. 89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up. Eur J Nucl Med Mol Imaging 2018;45:2300-6. [PMID: 30058029 DOI: 10.1007/s00259-018-4099-8] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
50 Patel SA, DeMichele A. Adding Adjuvant Systemic Treatment after Neoadjuvant Therapy in Breast Cancer: Review of the Data. Curr Oncol Rep 2017;19:56. [PMID: 28733827 DOI: 10.1007/s11912-017-0613-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
51 Torigoe H, Shien K, Takeda T, Yoshioka T, Namba K, Sato H, Suzawa K, Yamamoto H, Soh J, Sakaguchi M, Tomida S, Tsukuda K, Miyoshi S, Toyooka S. Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations. Cancer Sci 2018;109:1493-502. [PMID: 29532558 DOI: 10.1111/cas.13571] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
52 Feng Z, Wen H, Ju X, Bi R, Chen X, Yang W, Wu X. Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancers. Oncotarget 2017;8:32848-55. [PMID: 28416763 DOI: 10.18632/oncotarget.15858] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
53 Kim HJ, Oh SC. Novel Systemic Therapies for Advanced Gastric Cancer. J Gastric Cancer 2018;18:1-19. [PMID: 29629216 DOI: 10.5230/jgc.2018.18.e3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
54 Ahn S, Kim HJ, Kim M, Chung YR, Kang E, Kim EK, Kim SH, Kim YJ, Kim JH, Kim IA, Park SY. Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer. Cancer Res Treat 2018;50:1418-32. [PMID: 29361816 DOI: 10.4143/crt.2017.552] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
55 Mittendorf EA, Vila J, Tucker SL, Chavez-MacGregor M, Smith BD, Symmans WF, Sahin AA, Hortobagyi GN, Hunt KK. The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment. JAMA Oncol. 2016;2:929-936. [PMID: 26986538 DOI: 10.1001/jamaoncol.2015.6478] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 12.4] [Reference Citation Analysis]
56 Chong QY, You ML, Pandey V, Banerjee A, Chen YJ, Poh HM, Zhang M, Ma L, Zhu T, Basappa S, Liu L, Lobie PE. Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2+/ER+ mammary carcinoma. Oncotarget 2017;8:74188-208. [PMID: 29088778 DOI: 10.18632/oncotarget.18431] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
57 Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Arteaga CL. HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clin Cancer Res 2017;23:4323-34. [PMID: 28381415 DOI: 10.1158/1078-0432.CCR-16-2287] [Cited by in Crossref: 37] [Cited by in F6Publishing: 16] [Article Influence: 7.4] [Reference Citation Analysis]
58 Goh G, Schmid R, Guiver K, Arpornwirat W, Chitapanarux I, Ganju V, Im SA, Kim SB, Dechaphunkul A, Maneechavakajorn J, Spector N, Yau T, Afrit M, Ahmed SB, Johnston SR, Gibson N, Uttenreuther-Fischer M, Herrero J, Swanton C. Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine. PLoS Med 2016;13:e1002136. [PMID: 27923043 DOI: 10.1371/journal.pmed.1002136] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
59 Shin HC, Han W, Moon HG, Park IA, Noh DY. Patients with Concordant Triple-Negative Phenotype between Primary Breast Cancers and Corresponding Metastases Have Poor Prognosis. J Breast Cancer 2016;19:268-74. [PMID: 27721876 DOI: 10.4048/jbc.2016.19.3.268] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
60 Ding J, Hu P, Chen J, Wu X, Cao Y. The importance of tissue confirmation of metastatic disease in patients with breast cancer: lesson from a brain metastasis case. Oncoscience 2016;3:268-74. [PMID: 28050577 DOI: 10.18632/oncoscience.320] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
61 Martin-Castillo B, Lopez-Bonet E, Cuyàs E, Viñas G, Pernas S, Dorca J, Menendez JA. Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas. Oncotarget 2015;6:32317-38. [PMID: 26474458 DOI: 10.18632/oncotarget.6094] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
62 He XH, Zhu W, Yuan P, Jiang S, Li D, Zhang HW, Liu MF. miR-155 downregulates ErbB2 and suppresses ErbB2-induced malignant transformation of breast epithelial cells. Oncogene 2016;35:6015-25. [PMID: 27065318 DOI: 10.1038/onc.2016.132] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
63 Guarneri V, Dieci MV, Frassoldati A, Maiorana A, Ficarra G, Bettelli S, Tagliafico E, Bicciato S, Generali DG, Cagossi K, Bisagni G, Sarti S, Musolino A, Ellis C, Crescenzo R, Conte P. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer. Oncologist 2015;20:1001-10. [PMID: 26245675 DOI: 10.1634/theoncologist.2015-0138] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 8.0] [Reference Citation Analysis]
64 Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF; Residual Disease Characterization Working Group of the Breast International Group-North American Breast Cancer Group Collaboration. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Mod Pathol 2015;28:1185-201. [PMID: 26205180 DOI: 10.1038/modpathol.2015.74] [Cited by in Crossref: 117] [Cited by in F6Publishing: 103] [Article Influence: 16.7] [Reference Citation Analysis]
65 Hassan B, Akcakanat A, Sangai T, Evans KW, Adkins F, Eterovic AK, Zhao H, Chen K, Chen H, Do KA, Xie SM, Holder AM, Naing A, Mills GB, Meric-Bernstam F. Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. Oncotarget 2014;5:8544-57. [PMID: 25261369 DOI: 10.18632/oncotarget.2337] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
66 Blancafort A, Giró-Perafita A, Oliveras G, Palomeras S, Turrado C, Campuzano Ò, Carrión-Salip D, Massaguer A, Brugada R, Palafox M, Gómez-Miragaya J, González-Suárez E, Puig T. Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs. PLoS One 2015;10:e0131241. [PMID: 26107737 DOI: 10.1371/journal.pone.0131241] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
67 Chung A, Choi M, Han BC, Bose S, Zhang X, Medina-Kauwe L, Sims J, Murali R, Taguiam M, Varda M, Schiff R, Giuliano A, Cui X. Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer. Clin Breast Cancer 2015;15:448-457.e2. [PMID: 26248960 DOI: 10.1016/j.clbc.2015.06.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
68 Vicario R, Peg V, Morancho B, Zacarias-Fluck M, Zhang J, Martínez-Barriocanal Á, Navarro Jiménez A, Aura C, Burgues O, Lluch A, Cortés J, Nuciforo P, Rubio IT, Marangoni E, Deeds J, Boehm M, Schlegel R, Tabernero J, Mosher R, Arribas J. Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies. PLoS One 2015;10:e0129876. [PMID: 26075403 DOI: 10.1371/journal.pone.0129876] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
69 Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G, Dixon JM, Esserman LJ, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Viale G, Cameron D; Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol. 2015;26:1280-1291. [PMID: 26019189 DOI: 10.1093/annonc/mdv161] [Cited by in Crossref: 113] [Cited by in F6Publishing: 97] [Article Influence: 16.1] [Reference Citation Analysis]
70 Abravanel DL, Belka GK, Pan TC, Pant DK, Collins MA, Sterner CJ, Chodosh LA. Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy. J Clin Invest 2015;125:2484-96. [PMID: 25961456 DOI: 10.1172/JCI74883] [Cited by in Crossref: 72] [Cited by in F6Publishing: 51] [Article Influence: 10.3] [Reference Citation Analysis]
71 Meric-Bernstam F, Johnson A, Holla V, Bailey AM, Brusco L, Chen K, Routbort M, Patel KP, Zeng J, Kopetz S, Davies MA, Piha-Paul SA, Hong DS, Eterovic AK, Tsimberidou AM, Broaddus R, Bernstam EV, Shaw KR, Mendelsohn J, Mills GB. A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst 2015;107:djv098. [PMID: 25863335 DOI: 10.1093/jnci/djv098] [Cited by in Crossref: 119] [Cited by in F6Publishing: 116] [Article Influence: 17.0] [Reference Citation Analysis]
72 Nuciforo P, Radosevic-Robin N, Ng T, Scaltriti M. Quantification of HER family receptors in breast cancer. Breast Cancer Res. 2015;17:53. [PMID: 25887735 DOI: 10.1186/s13058-015-0561-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
73 Ishimine Y, Goto A, Watanabe Y, Yajima H, Nakagaki S, Yabana T, Adachi T, Kondo Y, Kasai K. Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent? Case Rep Gastrointest Med 2015;2015:132030. [PMID: 25893119 DOI: 10.1155/2015/132030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
74 Yoshimoto M, Kurihara H, Fujii H. Theragnostic imaging using radiolabeled antibodies and tyrosine kinase inhibitors. ScientificWorldJournal 2015;2015:842101. [PMID: 25874259 DOI: 10.1155/2015/842101] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
75 Criscitiello C, André F, Thompson AM, De Laurentiis M, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I, Orsi F, Goldhirsch A, Curigliano G. Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. Breast Cancer Res 2014;16:205. [PMID: 25032257 DOI: 10.1186/bcr3630] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
76 Ge WK, Yang B, Zuo WS, Zheng G, Dai YQ, Han C, Yang L, Zheng MZ. Evaluation of hormone receptor, human epidermal growth factor receptor-2 and Ki-67 with core needle biopsy and neoadjuvant chemotherapy effects in breast cancer patients. Thorac Cancer 2015;6:64-9. [PMID: 26273337 DOI: 10.1111/1759-7714.12133] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
77 Niu J, Gelbspan D, Weitz D, Markman M, Quan W. HER2-positive, trastuzumab-resistant metastatic esophageal cancer presenting with brain metastasis after durable response to dual HER2 blockade: a case report. J Gastrointest Oncol. 2014;5:E103-E108. [PMID: 25436131 DOI: 10.3978/j.issn.2078-6891.2014.045] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
78 Brufsky AM. Current Approaches and Emerging Directions in HER2-resistant Breast Cancer. Breast Cancer (Auckl) 2014;8:109-18. [PMID: 25125981 DOI: 10.4137/BCBCR.S9453] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
79 Fabi A, Mottolese M, Segatto O. Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic. J Mol Med (Berl) 2014;92:681-95. [PMID: 24861025 DOI: 10.1007/s00109-014-1169-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
80 Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014;25:282-303. [PMID: 24651011 DOI: 10.1016/j.ccr.2014.02.025] [Cited by in Crossref: 537] [Cited by in F6Publishing: 490] [Article Influence: 67.1] [Reference Citation Analysis]
81 Teshome M, Hunt KK. Neoadjuvant therapy in the treatment of breast cancer. Surg Oncol Clin N Am 2014;23:505-23. [PMID: 24882348 DOI: 10.1016/j.soc.2014.03.006] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 7.8] [Reference Citation Analysis]
82 Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, Yelensky R, Pérez-Fidalgo JA, Wang Y, Palmer GA, Ross JS, Miller VA, Su X, Eroles P, Barrera JA, Burgues O, Lluch AM, Zheng X, Sahin A, Stephens PJ, Mills GB, Cronin MT, Gonzalez-Angulo AM. Concordance of genomic alterations between primary and recurrent breast cancer. Mol Cancer Ther 2014;13:1382-9. [PMID: 24608573 DOI: 10.1158/1535-7163.MCT-13-0482] [Cited by in Crossref: 75] [Cited by in F6Publishing: 47] [Article Influence: 9.4] [Reference Citation Analysis]
83 Chung A, Cui X, Audeh W, Giuliano A. Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance. Clin Breast Cancer 2013;13:223-32. [PMID: 23829888 DOI: 10.1016/j.clbc.2013.04.001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
84 Singh A, Sirohi B, Gupta S. Biomarkers in Breast Cancer and the Implications of Their Discordance. Curr Breast Cancer Rep 2013;5:266-74. [DOI: 10.1007/s12609-013-0126-8] [Reference Citation Analysis]
85 Raina D, Uchida Y, Kharbanda A, Rajabi H, Panchamoorthy G, Jin C, Kharbanda S, Scaltriti M, Baselga J, Kufe D. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. Oncogene 2014;33:3422-31. [PMID: 23912457 DOI: 10.1038/onc.2013.308] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 6.4] [Reference Citation Analysis]
86 Esteva FJ, Franco SX, Hagan MK, Brewster AM, Somer RA, Williams W, Florance AM, Turner S, Stein S, Perez A. An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer. Oncologist 2013;18:661-6. [PMID: 23697602 DOI: 10.1634/theoncologist.2012-0129] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
87 Meric-Bernstam F, Farhangfar C, Mendelsohn J, Mills GB. Building a personalized medicine infrastructure at a major cancer center. J Clin Oncol 2013;31:1849-57. [PMID: 23589548 DOI: 10.1200/JCO.2012.45.3043] [Cited by in Crossref: 76] [Cited by in F6Publishing: 36] [Article Influence: 8.4] [Reference Citation Analysis]
88 Ithimakin S, Day KC, Malik F, Zen Q, Dawsey SJ, Bersano-Begey TF, Quraishi AA, Ignatoski KW, Daignault S, Davis A, Hall CL, Palanisamy N, Heath AN, Tawakkol N, Luther TK, Clouthier SG, Chadwick WA, Day ML, Kleer CG, Thomas DG, Hayes DF, Korkaya H, Wicha MS. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res. 2013;73:1635-1646. [PMID: 23442322 DOI: 10.1158/0008-5472.can-12-3349] [Cited by in Crossref: 170] [Cited by in F6Publishing: 104] [Article Influence: 18.9] [Reference Citation Analysis]
89 Hess KR, Esteva FJ. Effect of HER2 status on distant recurrence in early stage breast cancer. Breast Cancer Res Treat 2013;137:449-55. [PMID: 23225147 DOI: 10.1007/s10549-012-2366-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
90 Niu J, Weber J, Gelbspan D. Change of HER2 status in metastatic esophageal adenocarcinoma: heterogeneity of the disease? Case report and review of literature. J Gastrointest Oncol 2012;3:358-61. [PMID: 23205313 DOI: 10.3978/j.issn.2078-6891.2012.036] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
91 Chan A, Morey A, Brown B, Hastrich D, Willsher P, Ingram D. A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease. BMC Cancer 2012;12:555. [PMID: 23176370 DOI: 10.1186/1471-2407-12-555] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
92 Manjili MH, Najarian K, Wang XY. Signatures of tumor-immune interactions as biomarkers for breast cancer prognosis. Future Oncol 2012;8:703-11. [PMID: 22764768 DOI: 10.2217/fon.12.57] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
93 Gonzalez-Angulo AM, Liu S, Chen H, Chavez-Macgregor M, Sahin A, Hortobagyi GN, Mills GB, Do KA, Meric-Bernstam F. Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy. Ann Oncol 2013;24:909-16. [PMID: 23139263 DOI: 10.1093/annonc/mds530] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
94 Chandarlapaty S, Sakr RA, Giri D, Patil S, Heguy A, Morrow M, Modi S, Norton L, Rosen N, Hudis C. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin Cancer Res. 2012;18:6784-6791. [PMID: 23092874 DOI: 10.1158/1078-0432.ccr-12-1785] [Cited by in Crossref: 123] [Cited by in F6Publishing: 75] [Article Influence: 12.3] [Reference Citation Analysis]
95 Puglisi F, Minisini AM, De Angelis C, Arpino G. Overcoming treatment resistance in HER2-positive breast cancer: potential strategies. Drugs 2012;72:1175-93. [PMID: 22686613 DOI: 10.2165/11634000-000000000-00000] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
96 Kołacińska A, Chałubińska J, Błasińska-Morawiec M, Dowgier-Witczak I, Fendler W, Kordek R, Morawiec Z. Pathological complete response in younger and older breast cancer patients. Arch Med Sci 2012;8:310-5. [PMID: 22662005 DOI: 10.5114/aoms.2012.28559] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
97 Vaz-Luis I, Ottesen RA, Hughes ME, Marcom PK, Moy B, Rugo HS, Theriault RL, Wilson J, Niland JC, Weeks JC. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res. 2012;14:R129. [PMID: 23025714 DOI: 10.1186/bcr3324] [Cited by in Crossref: 78] [Cited by in F6Publishing: 79] [Article Influence: 7.8] [Reference Citation Analysis]
98 Tagliabue E, Campiglio M, Balsari A, Ménard S. PET Prediction of Response to Trastuzumab in ErbB2-Positive Human Xenograft Model. J Nucl Med 2012;53:1654-5. [DOI: 10.2967/jnumed.112.108068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
99 Meric-Bernstam F, Mills GB. Overcoming implementation challenges of personalized cancer therapy. Nat Rev Clin Oncol. 2012;9:542-548. [PMID: 22850751 DOI: 10.1038/nrclinonc.2012.127] [Cited by in Crossref: 90] [Cited by in F6Publishing: 73] [Article Influence: 9.0] [Reference Citation Analysis]
100 Choi BK, Fan X, Deng H, Zhang N, An Z. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells. Cancer Med 2012;1:28-38. [PMID: 23342251 DOI: 10.1002/cam4.10] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
101 Nahta R. New developments in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) 2012;4:53-64. [PMID: 23869176 DOI: 10.2147/BCTT.S24976] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
102 Dawood S, Gonzalez-Angulo AM. To biopsy or not to biopsy: is that the only question? Oncologist 2012;17:151-3. [PMID: 22267854 DOI: 10.1634/theoncologist.2011-0432] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
103 Puig T, Aguilar H, Cufí S, Oliveras G, Turrado C, Ortega-Gutiérrez S, Benhamú B, López-Rodríguez ML, Urruticoechea A, Colomer R. A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines. Breast Cancer Res 2011;13:R131. [PMID: 22177475 DOI: 10.1186/bcr3077] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 4.8] [Reference Citation Analysis]
104 Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, Palla SL, Tokuda Y, Gonzalez-Angulo AM, Hortobagyi GN, Ueno NT. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 2012;30:593-9. [PMID: 22124109 DOI: 10.1200/JCO.2010.33.8889] [Cited by in Crossref: 256] [Cited by in F6Publishing: 124] [Article Influence: 23.3] [Reference Citation Analysis]
105 Ceugnart L, Coudert B, Dalenc F, Guinebretiere J, Rouanet P, Toledano A. Les traitements néoadjuvants (hors cancer du sein inflammatoire). Oncologie 2011;13:658-80. [DOI: 10.1007/s10269-011-2075-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
106 Higgins MJ, Baselga J. Targeted therapies for breast cancer. J Clin Invest. 2011;121:3797-3803. [PMID: 21965336 DOI: 10.1172/jci57152] [Cited by in Crossref: 232] [Cited by in F6Publishing: 131] [Article Influence: 21.1] [Reference Citation Analysis]
107 Akay CL, Meric-Bernstam F, Hunt KK, Grubbs EG, Bedrosian I, Tucker SL, Kuerer HM, Hoffman KE, Babiera GV, Strom EA, Buchholz TA, Mittendorf EA. Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol 2012;19:901-7. [PMID: 21861223 DOI: 10.1245/s10434-011-2006-7] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
108 Khasraw M, Brogi E, Seidman AD. The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury? Curr Oncol Rep 2011;13:17-25. [PMID: 21053108 DOI: 10.1007/s11912-010-0137-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
109 Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, Burgues O, Lluch AM, Chen H, Hortobagyi GN, Mills GB, Meric-Bernstam F. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther 2011;10:1093-101. [PMID: 21490305 DOI: 10.1158/1535-7163.MCT-10-1089] [Cited by in Crossref: 171] [Cited by in F6Publishing: 109] [Article Influence: 15.5] [Reference Citation Analysis]
110 Mittendorf EA, Jeruss JS, Tucker SL, Kolli A, Newman LA, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 2011;29:1956-62. [PMID: 21482989 DOI: 10.1200/JCO.2010.31.8469] [Cited by in Crossref: 86] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
111 Yi M, Buchholz TA, Meric-Bernstam F, Bedrosian I, Hwang RF, Ross MI, Kuerer HM, Luo S, Gonzalez-Angulo AM, Buzdar AU, Symmans WF, Feig BW, Lucci A, Huang EH, Hunt KK. Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg 2011;253:572-9. [PMID: 21209588 DOI: 10.1097/SLA.0b013e318208fc2a] [Cited by in Crossref: 40] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
112 Scaltriti M, Eichhorn PJ, Cortés J, Prudkin L, Aura C, Jiménez J, Chandarlapaty S, Serra V, Prat A, Ibrahim YH, Guzmán M, Gili M, Rodríguez O, Rodríguez S, Pérez J, Green SR, Mai S, Rosen N, Hudis C, Baselga J. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A 2011;108:3761-6. [PMID: 21321214 DOI: 10.1073/pnas.1014835108] [Cited by in Crossref: 195] [Cited by in F6Publishing: 186] [Article Influence: 17.7] [Reference Citation Analysis]
113 Gutierrez C, Schiff R. HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 2011;135:55-62. [PMID: 21204711 DOI: 10.5858/2010-0454-RAR.1] [Cited by in Crossref: 80] [Cited by in F6Publishing: 129] [Article Influence: 7.3] [Reference Citation Analysis]
114 Gutierrez C, Schiff R. HER2: biology, detection, and clinical implications. Arch Pathol Lab Med. 2011;135:55-62. [PMID: 21204711 DOI: 10.1043/2010-0454-rar.1] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
115 Abramson V, Arteaga CL. New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available. Clin Cancer Res 2011;17:952-8. [PMID: 21248299 DOI: 10.1158/1078-0432.CCR-09-1947] [Cited by in Crossref: 54] [Cited by in F6Publishing: 25] [Article Influence: 4.9] [Reference Citation Analysis]
116 Sivarajan L, Sivarajan KM, Natarelli J, Aijaz F. Change in HER-2/neu Status from Negative to Positive following Treatment in Breast Cancer: A Case Report. Case Rep Oncol 2011;4:19-24. [PMID: 21526002 DOI: 10.1159/000324114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
117 . Bibliography. Current world literature. Curr Opin Obstet Gynecol 2011;23:58-63. [PMID: 21191271 DOI: 10.1097/GCO.0b013e3283432017] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
118 Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF; American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145. [PMID: 17159189 DOI: 10.5858/arpa.2013-0953-sa] [Cited by in Crossref: 612] [Cited by in F6Publishing: 311] [Article Influence: 38.3] [Reference Citation Analysis]